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Objective: In healthy joints, a zone of calciﬁed cartilage (ZCC) provides the mechanical integration be-
tween articular cartilage and subchondral bone. Recapitulation of this architectural feature should serve
to resist the constant shear force from the movement of the joint and prevent the delamination of tissue-
engineered cartilage. Previous approaches to create the ZCC at the cartilageesubstrate interface have
relied on strategic use of exogenous scaffolds and adhesives, which are susceptible to failure by degra-
dation and wear. In contrast, we report a successful scaffold-free engineering of ZCC to integrate tissue-
engineered cartilage and a porous biodegradable bone substitute, using sheep bone marrow stromal cells
(BMSCs) as the cell source for both cartilaginous zones.
Design: BMSCs were predifferentiated to chondrocytes, harvested and then grown on a porous calcium
polyphosphate substrate in the presence of triiodothyronine (T3). T3 was withdrawn, and additional
predifferentiated chondrocytes were placed on top of the construct and grown for 21 days.
Results: This protocol yielded two distinct zones: hyaline cartilage that accumulated proteoglycans and
collagen type II, and calciﬁed cartilage adjacent to the substrate that additionally accumulated mineral and
collagen typeX. Constructswith the calciﬁed interfacehad comparable compressive strength tonative sheep
osteochondral tissue and higher interfacial shear strength compared to control without a calciﬁed zone.
Conclusion: This protocol improves on the existing scaffold-free approaches to cartilage tissue engi-
neering by incorporating a calciﬁed zone. Since this protocol employs no xenogeneic material, it will be
appropriate for use in preclinical large-animal studies.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In a synovial joint, articular cartilage bears both compressive and
shear forces to facilitate weight bearing and movement. Once: R.A. Kandel, Department of
pital, 600 University Avenue,
8516; Fax: 1-(416)-586-8719.
W.L. Stanford, Sprott Centre
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ternational. Published by Elsevier Ldamaged, these mechanical forces contribute to the progression of
cartilage damage, resulting in loss of cartilage and subchondral bone
remodeling. Tissue engineering is widely regarded as a promising
technology to generate constructs that could replace damaged
cartilage and bone1. A wide range of osteochondral tissue engineer-
ing strategies are under investigation2, including our effort to pro-
duce biphasic constructs that consist of scaffold-free cartilage tissue
formed by articular chondrocytes or bone marrow stromal cells
(BMSCs) on porous bone substitutes (calcium polyphosphate)3,4.
Calcium polyphosphate is a biodegradable ceramic with excellent
load-bearing and osseointegrative properties5,6. In our design,
ingrowth of bone into calcium polyphosphate holds the biphasic
construct inplace and provides support against compressive force ontd. All rights reserved.
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chanically competent interface between the cartilage and its sub-
strate is needed. Preventing cartilage delamination is a common
challenge shared by many cartilage repair strategies7,8.
Healthy cartilage tissue interfaces with bone in vivo through a
zone of calciﬁed cartilage (ZCC), which enhances mechanical inte-
gration by redistributing forces acting at the interface9. BMSCs are
suitable for creating calciﬁed cartilage, because they can be differ-
entiated to produce cartilage tissues that mineralize their matrix10.
While chondrocytes from the deep zone of articular cartilage can
also yield calciﬁed cartilage in vitro11, BMSCs can be obtained
without donor site morbidity and expanded to clinically relevant
numbers. Furthermore, in vivo studies have shown that BMSC-
derived cartilage can maintain their non-calciﬁed phenotype after
being implanted in a joint cavity12,13, demonstrating the potential
of BMSCs to produce both calciﬁed and non-calciﬁed cartilage.
However, to use BMSCs as a single source of cells to create cartilage
tissues with a calciﬁed cartilaginous interface, limiting minerali-
zation of BMSC-derived cartilage to the interface will be crucial for
the success of these implants.
Using BMSCs as the cell source, we report the ﬁrst successful
engineering of an osteochondral-like construct that incorporates a
ZCC at the cartilage-calcium polyphosphate interface without the
use of a scaffold as the cartilage tissue forms on top of a substrate. A
stepwise culturing strategy enabled the selective activation of
BMSC-derived chondrocytes to induce mineralization only at the
interface, while avoiding mineralization in the contiguous cartilage
tissue, thus conferring localized calciﬁed and hyaline zones to the
engineered cartilage tissue. This approach is suitable for clinical use
as the BMSCs were expanded in media supplemented with autol-
ogous serum and the construct cultured in serum-free, deﬁned
media, so this strategy can be directly translated to in vivo pre-
clinical studies.
Materials and methods
Chondrogenic predifferentiation of BMSCs in membrane cultures
Sheep BMSCs were isolated and expanded from bone marrow
aspirates taken from ewes aged between 2 and 5 years as previ-
ously described4 using autologous serum (see Supplementary
Methods). To differentiate BMSCs to chondrocytes, 2.0  106
BMSCs were seeded onto 12 mm cell culture inserts (0.2 mm pore
size; Millipore, Billerica, MA) that were coated with collagen type
IV (50 mg/insert; SigmaeAldrich, Oakville, ON, Canada). Cells were
cultured in a deﬁned chondrogenic media composed of high-
glucose Dulbecco's modiﬁed Eagle medium (DMEM; Life Technol-
ogies, Burlington, ON, Canada), 1 insulin-transferrin-selenium
plus (ITSþ) cell culture supplement (BD Biosciences, Bedford,
MA), 100 nM dexamethasone (SigmaeAldrich), 100 mg/mL ascorbic
acid (SigmaeAldrich) and 10 ng/mL transforming growth factor-b3
(TGF-b3; R&D Systems, Minneapolis, MN). For the ﬁrst 72 h,
chondrogenic media was additionally supplemented with 10 mM
blebbistatin (Cayman Chemical, Ann Arbor, MI) to inhibit sponta-
neous detachment of cells. Media was changed every 2e3 days.
After 3 weeks of culture, cells (herein referred to as prediffer-
entiated chondrocytes) were isolated by digesting the tissue in 0.5%
(w/v) collagenase (Roche Diagnostics, Indianapolis, IN) for 2 h at
37C.
Preparation of porous calcium polyphosphate substrates with a
hydroxyapatite coating
Porous calcium polyphosphate disks of 4 mm diameter and
2 mm height were prepared from gravity-sintered 75e150 mmcalcium polyphosphate particles as previously described14. Disks
were incubated in phosphate-buffered saline (PBS) for 1 week.
Then, a thin, submicron hydroxyapatite layer was deposited over
the disks using a solegel processing method. This hydroxyapatite
layer was intended to serve as a ‘barrier’ coating inhibiting the rate
of release of calcium polyphosphate degradation products during
in vitro cartilage formation15. The sol was prepared with triethyl
phosphite and calcium nitrate tetrahydrate (SigmaeAldrich) as
previously described16. Disks were dipped into the sol gel side-
ways for 8 s and withdrawn at a speed of 20 cm/min using a
stepper motor-driven actuator, air-dried for 10 min and annealed
for 15 min at 210C. To ensure a continuous barrier coating, coated
disks were dipped again, annealed at 500C for 20 min and
gradually cooled. The coated disks were placed in Tygon tubing to
create a well-like structure and subsequently sterilized by g-irra-
diation (2.5 MRad).
Optimizing the mineralizing culture condition for predifferentiated
chondrocytes
To ﬁnd a culture condition in which predifferentiated chon-
drocytes would form calciﬁed cartilage tissue, predifferentiated
chondrocytes were placed on the top surface of porous calcium pol-
yphosphate substrates (1.5106 cells/substrate)andcultured inbasal
construct media composed of DMEM, 1 ITSþ, 100 mg/mL ascorbic
acid, 50 mg/mL L-proline and 10 mM b-glycerophosphate (Sigmae
Aldrich). Todeterminewhich conditionwould inducemineralization,
100 nM dexamethasone, 3 nM triiodothyronine (T3) or 100 nM reti-
noic acid (all SigmaeAldrich) were added to cultures. The cultures
were harvested at various times up to 21 days for further study.
Tissue culture of multiphasic constructs
Predifferentiated chondrocytes were placed on the top surface
of porous calcium polyphosphate substrates (1.0  106 cells/sub-
strate) and cultured in basal construct media, with or without 3 nM
T3. T3 was withdrawn at day 4. At day 5, additional prediffer-
entiated chondrocyteswere placed on top of the existing constructs
(1.5  106 cells/construct). The multi-layered constructs were
maintained under the same culture conditions for up to 21 days.
This protocol is shown in Fig. 1.
Visualization and quantiﬁcation of alkaline phosphate (ALP) activity
To visualize ALP activity, tissues were removed from their sub-
strates and ﬁxed in 10% neutral buffered formalin for 1 h. Then,
samples were incubated in 30% (w/v) sucrose overnight at 4C and
snap-frozen in Tissue-Tek OCT compound (Sakura Finetek, Tor-
rance, CA). 6 mm cross-section cryosections were cut and mounted
on silanized glass slides. Sections were incubated in azo dye
(Naphthol AS-MX phosphate and Fast Blue BB salt, both Sigma-
eAldrich) for 10 min, counterstained with eosin, dried and
mounted with coverslips. To quantify the ALP activity, cells were
isolated from tissues by digestion in 0.5% collagenase for 2 h and
lysed by sonication for 15 min in 0.2 M Tris pH 7.4 buffer. Activity
levels were quantiﬁed with p-nitrophenol phosphate (Sigma-
eAldrich) and measuring the absorbance at 405 nm against a
standard curve of p-nitrophenol11. Values were normalized to the
lysate's DNA content (see Biochemical Analysis).
Gene expression analysis
Predifferentiated chondrocytes (1.5  106 cells/substrate) were
cultured on porous calcium polyphosphate substrates in basal
construct media with 4 days of 3 nM T3. T3 was removed after 4
Fig. 1. Line diagram of the tissue culture protocol used for forming scaffold-free multiphasic osteochondral-like constructs.
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remainder of the 21 days of culture. Controls were cells that were
untreated and grown in the same media. Tissues were removed
from their substrates at day 4 and 21 and homogenized in 1 mL
TRIzol reagent (Life Technologies) by bead milling. Total RNA was
then extracted and reverse-transcribed using SuperScript VILO
cDNA Synthesis Kit (Life Technologies). Quantitative PCR was per-
formed using a LightCycler 96 Real-Time PCR System (Roche Di-
agnostics) and SYBR GreenER master mix (Life Technologies) with
gene-speciﬁc primers (Supplementary Table 1).Micro-computed tomography (mCT) imaging
Constructs were imaged using a SkyScan 1174v2 mCT scanner
(Bruker, Belgium). Scanning was performed at 50 kV and 800 mA
through a 0.25 mm aluminum shield with a voxel size of 6.9 mm.
After reconstruction, cross-sectional tomographs were obtained
with the software provided by the manufacturer.Histological analysis of whole constructs
Constructs were ﬁxed in 10% neutral buffered formalin over-
night and inﬁltrated using the Osteo-Bed bone embedding kit
(Polysciences Inc., Warrington, PA). Sections were cut and ground
to ~50 mm thickness, stained with toluidine blue and light green
and visualized under light microscopy.Histological analysis of cartilaginous tissues
Tissue mineral and proteoglycan accumulation was visualized
by staining histological sections (see Supplementary Methods)
with von Kossa and toluidine blue. Orientation of collagen ﬁbrils
was visualized by polarized light microscopy of trichrome-
stained sections. Visualization for collagens types I, II and X
were visualized by immunoﬂuorescence (see Supplementary
Methods).
Biochemical analysis of extracellular matrix and mineral
accumulation
Tissues were digested in 40 mg/mL papain (SigmaeAldrich) and
DNA, glycosaminoglycan and hydroxyproline contents were quan-
tiﬁed as previously described17. To measure mineral accumulation,
the tissues were lyophilized, dry weights measured, and then
digested in 3 N hydrochloric acid at 90C for 2 h. The pH was
adjusted to 4.0 with 1.5 M acetate buffer. Phosphate content was
determined using the heteropoly blue assay and measuring the
absorbance at 620 nm. Calcium content was determined using the
o-cresolphthalein complexone assay and measuring the absor-
bance at 570 nm.
Mechanical testing of multiphasic constructs
On day 21 of culture, the equilibrium compressive modulus of
the multiphasic construct's cartilaginous tissue was determined by
W.D. Lee et al. / Osteoarthritis and Cartilage 23 (2015) 1307e13151310stress relaxation testing on the Mach-1 mechanical tester (Bio-
Momentum, Laval, Canada) with a 0.65 mm-diameter indenter as
previously described4. Interfacial shear strength was determined
by applying a force at the interface region of these samples using a
specially designed jig attached to an Instron universal testing ma-
chine as previously described15 (see Supplementary Methods).
Statistical testing
All values are expressed as mean ± 95% conﬁdence intervals (CI).
Each experiment was carried out with three donor animals (N ¼ 3).
Univariate analysis of variance and Tukey post-hoc testing were
used to analyze ALP activity levels on days 0e4, accumulation of
GAG, total collagen and mineral contents, as well as the compres-
sive moduli of the constructs. The interfacial shear strength data of
the constructs were analyzed using t test. To account for the wide
animal-to-animal variability, ALP activity levels on days 7, 10 and 14
were each analyzed using paired t test. Similarly, gene expression
levels on days 4 and 21 were log-transformed and analyzed using
paired t test.
Results
Generation of calciﬁed cartilage at the calcium polyphosphate
interface with predifferentiated chondrocytes
To engineer a multiphasic construct that incorporates a ZCC at
the cartilage-calcium polyphosphate interface using prediffer-
entiated chondrocytes, we ﬁrst sought to establish a cultureFig. 2. Predifferentiated chondrocytes formed cartilaginous tissues on porous calcium po
differentiated chondrocytes cultured for 7 days with 3 nM triiodothyronine (T3) or 100 nM
detected. *P ¼ 0.043 between þT3 eDex and þT3 þDex; P ¼ 0.045 between þT3 eDex an
formed by culturing 2  106 predifferentiated chondrocytes on the substrates with 3 nM T3
Asterisk denotes the original location of the substrate. Scale bar ¼ 200 mm. (C) Cross-secti
numbers of seeded cells: 2  106 (left), 1.5  106 (middle) and 1.0  106 (right) prediffer
mineralized zone (green) and the substrate (gray). Arrows indicate the lack of separation becondition in which predifferentiated chondrocytes could be
cultured on porous calcium polyphosphate substrates to form
mineralized cartilage tissue. Triiodothyronine (T3)18, retinoic acid19
and dexamethasone10 have all been identiﬁed as potential inducers
of chondrocyte mineralization in vitro. We cultured prediffer-
entiated chondrocytes on calcium polyphosphate substrates with
either 3 nM T3 or 100 mM retinoic acid treatment in the presence or
absence of dexamethasone for 1 week, and then quantiﬁed the ALP
activity of the cells as an indicator of chondrocyte mineralization
potential20,21. ALP activity was the highest in predifferentiated
chondrocytes cultured in the absence of dexamethasone with the
T3 treatment [Fig. 2(A)]. While ALP activity was also increased with
the retinoic acid treatment, continued culture did not yield carti-
laginous tissues on calcium polyphosphate after 3 weeks (data not
shown). Therefore, treatment of predifferentiated chondrocytes
with T3 was selected for further study.
When 2  106 predifferentiated chondrocytes were cultured on
porous calcium polyphosphate substrates for 3 weeks, the
mineralized zone was found in the top of the tissue [Fig. 2(B)].
Between this mineralized zone and the substrate was an inter-
mediary zone of non-mineralized cartilage, composed of cells with
round morphology and extracellular matrix rich in proteoglycans.
Changing the concentration of T3 treatment did not change the
location of the mineralized zone (data not shown). However,
when the number of initially seeded predifferentiated chon-
drocytes was decreased, the distance between the cartila-
geesubstrate interface and the zone of mineralized cartilage also
decreased [Fig. 2(C and D)]. At an initial seeding of 1  106 pre-
differentiated chondrocytes, the zone of mineralized cartilagelyphosphate substrates with a zone of mineralized cartilage. (A) ALP activity of pre-
retinoic acid (RA) with or without dexamethasone (Dex). Mean ± 95% CI, n ¼ 3, nd: not
d þRA eDex. (B) Von Kossa and toluidine blue-stained sections of cartilaginous tissue
for 3 weeks, showing mineralized zone occurring at the superﬁcial aspect of cartilage.
onal mCT tomographs and (D) and histology of 3-week-old constructs with decreasing
entiated chondrocytes. In (D) vertical bars denote non-mineralized cartilage (purple),
tween the mineralized zone and the substrate. Scale bar ¼ 1 mm (C) and 200 mm (D).
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arrows].
Short-term treatment of predifferentiated chondrocytes with T3 was
sufﬁcient to stimulate terminal differentiation
ALP activity levels of predifferentiated chondrocytes were
characterized over a 2-week culture period. T3-treated cells had a
signiﬁcantly increased ALP activity by day 4 [Fig. 3(A)]. Even though
the T3 treatment was withdrawn at day 4, the ALP activity level of
cells at day 7 was signiﬁcantly higher than those that had been
continuously treated with T3, and were comparable at days 10 and
14 [Fig. 3(B)].
To conﬁrm that the 4-day T3 treatment was sufﬁcient to
induce terminal differentiation of predifferentiated chon-
drocytes, gene expression levels were examined. As early as 4
days, collagen type X (Col10a1) expression was signiﬁcantly
higher in the T3-treated cells compared to the untreated control
[Fig. 3(G)]. By 21 days, T3-treated cells expressed less collagen
type II (Col2a1), aggrecan (Agc1) and Sox9, but greater Col10a1
and osteopontin (Spp1) compared to the non-treated controlsFig. 3. Short-term T3 treatment of predifferentiated chondrocytes was sufﬁcient to stimulate
the ﬁrst 4 days. In selected cultures, T3 treatment was withdrawn after 4 days (WD). (A) ALP
WD, compared to cells in which T3 treatment was continued (þ) for up to 14 days. *P ¼ 0.01
controls (). *P ¼ 0.013 (Col2a1 on day 21); P ¼ 0.031 (Agc1 on day 21); P ¼ 0.009 (Sox9 on
(Spp1 on day 21). Data points are color-coded for each animal throughout. Results are expr[Fig. 3(CeJ)]. This conﬁrmed that the 4-day T3 treatment of
predifferentiated chondrocytes had altered the differentiation of
these cells.
T3-treated predifferentiated chondrocytes did not induce ALP
activity in non-T3-treated predifferentiated chondrocytes
Based on this observation, a two-stage culture protocol was
developed (Fig. 1). To grow an interfacial zone of mineralized
cartilage, 1.0  106 predifferentiated chondrocytes were ﬁrst
seeded on porous calcium polyphosphate substrates, which was
the number of cells that had been previously determined to be
optimal for creating the mineralized cartilage at the interface, and
cultured in the presence of T3 [Fig. 2(C and D)]. T3 was withdrawn
at 4 days of culture, then 1.5  106 predifferentiated chondrocytes
were seeded on top of the existing tissue 1 day later and cultured in
the presence of b-glycerophosphate for up to 21 days to generate a
zone of non-mineralized cartilage. To conﬁrm that the T3-treated
cells would not stimulate the overlaid, non-T3-treated cells to
also mineralize, the tissues on calcium polyphosphate were har-
vested 5 days after the addition of the top layer of cells (10 days ofterminal differentiation. Predifferentiated chondrocytes were treated with 3 nM T3 for
activity during the ﬁrst 4 days. *P < 0.001 between days 0e4 & 2-4. (B) ALP activity of
4. (CeJ) Gene expression analysis of WD on days 4 and 21 compared to non-T3-treated
day 21); P ¼ 0.003 (Col10a1 on days 4 & 21); P ¼ 0.025 (Spp1 on day 4) and P ¼ 0.002
essed as mean ± 95% CI, n ¼ 3.
Fig. 4. Layer of predifferentiated chondrocytes treated with T3 did not induce the
overlaid layer of non-treated predifferentiated chondrocytes to activate ALP activity.
1  106 cells were cultured on porous calcium polyphosphate substrates with (A) or
without (B) 3 nM T3 for 4 days. On day 5, 1.5  106 cells were seeded on top of these
cells/tissue and cultured without T3. Cryosections of tissues from day 10 multiphasic
constructs were stained for ALP activity. The blue staining indicative of ALP was seen
only in the mineralizing layer (vertical bar). Asterisk denotes the location of where the
substrate would have been located prior to its removal, scale bar ¼ 200 mm.
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strated that ALP activity was present only in the calcifying bottom
layer (Fig. 4), demonstrating the lack of mineralization potential in
the top layer even though b-glycerophosphate was present.Fig. 5. A two-step culture protocol of predifferentiated chondrocytes on porous calcium poly
(A) Day 21 constructs with 4-day T3 treatment were processed undecalciﬁed, sectioned an
(brown). (BeI) Tissues were excised from the substrate and examined histologically for the
staining for the accumulation of different types of collagen (CeE, GeI). Constructs with T3-tr
denoted as eT3. Scale bars ¼ 200 mm. (J) Differential collagen ﬁber orientations on tissues
Fig. 6. Accumulation of extracellular matrix in T3-treated (þT3) tissues was less compared
Accumulated proteoglycan and (B) total collagenwere quantiﬁed and normalized by their DN
and Native. (C) Accumulation of mineral in tissue was quantiﬁed by measuring the calcium
data from sheep cartilage explants of femoral condyles. Results are expressed as mean ± 9Characterization of the multiphasic constructs
Constructs were grown for 21 days using the two-stage culture
protocol with or without the 4-day T3 treatment of the interfacial
layer and characterized using various methods. Histological ex-
amination of cartilage tissue on the calcium polyphosphate showed
two tissue zones. The upper zone of non-mineralized cartilage was
hyaline cartilage, rich in type II collagen and proteoglycan [Fig. 5(A,
B, D)]. The interfacial zone was calciﬁed cartilage, the mineral
staining with von Kossa staining and the extracellular matrix
staining with toluidine blue and type X collagen [Fig. 5(A, B, E)].
Ingrowth of tissue into upper parts of the porous calcium poly-
phosphate substrate was also observed, with the mineral clusters
directly in contact with the calcium polyphosphate particles
[Fig. 5(A)]. No type I collagenwas detected in either zone [Fig. 5(C)].
In contrast, control constructs not treated with T3 did not show a
bizonal composition as there was no ZCC, and there was an uneven
distribution of extracellular matrix [Fig. 5(FeI)]. Differential
collagen alignment in the tissue was detected using polarized light
microscopy. In the superﬁcial aspect, collagen was aligned parallel
to the surface. Elsewhere, collagenwas observed both pericellularly
and aligned orthogonal to the surface. Collagen, parallel to the
surface, was also observed in areaswithin the bottom layer of tissue
[Fig. 5(J)]. T3-treated constructs accumulated less proteoglycans
[Fig. 6(A)] and total collagens [Fig. 6(B)] compared to untreated
constructs, but the proteoglycan content was comparable to native
sheep cartilage. Tissues on T3-treated constructs accumulatedphosphate substrates produced cartilage tissue with a mineralized zone at the interface.
d stained to reveal the cartilaginous (purple), mineral (green) and substrate particles
distribution of mineral and proteoglycan accumulation (B, F), by immunoﬂuorescent
eated interfacial layer are denoted as þT3, and untreated (no T3) control constructs are
was seen by polarized light microscopy. Scale bar ¼ 100 mm.
to those in untreated (eT3) tissues, but comparable to native articular cartilage. (A)
A content. (A) *P ¼ 0.001, (B) *P ¼ 0.012 between þT3 and eT3; P ¼ 0.037 between þT3
and phosphate contents, normalized by tissue dry weight. **P < 0.001. Native denotes
5% CI, n ¼ 6.
Fig. 7. T3-treated constructs (þT3) exhibited comparable compressive strength as native sheep osteochondral explants and stronger shear strength than untreated constructs (eT3).
(A) Equilibrium compressive modulus was measured by stress relaxation test with a 0.65 mm-diameter indenter situated at the center of the tissue. *P ¼ 0.008, **P < 0.001. (B, C) A
shear load was applied to the cartilageesubstrate interface until failure. All substrates were identical in shape. The interfacial shear strength testing could not be performed on
osteochondral explants due to slippage of the cartilage tissue. (B) *P ¼ 0.003; (C) *P ¼ 0.016. Results are expressed as mean ± 95% CI, n ¼ 9 for constructs and 6 for explants.
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treated constructs did not [Fig. 6(C)].
T3-treated tissues had a comparable equilibrium compressive
modulus to that of osteochondral tissue obtained fromnative sheep
femoral condyles [Fig. 7(A), P ¼ 0.15]. The untreated constructs had
a signiﬁcantly higher equilibrium compressive modulus compared
to that of the T3-treated tissues, possibly due to their greater
extracellular matrix accumulation [Fig. 6(A, B)]. However, T3-
treated constructs could withstand a stronger shear force
[Fig. 7(B)] and absorb more energy [Fig. 7(C)] than untreated con-
structs. Histological assessment of the failed constructs conﬁrmed
that failure occurred at the interface (data not shown). This
demonstrated that the mineralized tissue at the interface [Fig. 5(A)]
enhanced the interfacial shear strength.
Discussion
A mechanically competent interface between the cartilage and
its substrate is required to resist the shear force generated by the
movement of the joint. Previous studies have sought to recreate the
ZCC that exists between hyaline cartilage and bone to reinforce this
interface with limited success22. To overcome this problem, we
successfully tissue-engineered osteochondral-like constructs with
BMSCs as the single cell source, in which cartilage tissue and a
porous bone substitute substrate were formed with an interfacial
ZCC without using any exogenous scaffolds in the cartilage tissue.
The two-stage culture protocol enabled the selective stimulation of
predifferentiated chondrocytes to form calciﬁed cartilage only at
the interface. Treatment of the initially seeded cells with T3
induced the terminal differentiation of cells. This resulted in a ZCC,
which, in addition to mineral, also contained collagens type II and X
and proteoglycans. These features were seen only in the part of the
tissue that was treatedwithmineralization-inducing T3, which was
adjacent to (and integrated with) the porous calcium poly-
phosphate substrate. The interfacial shear strength of constructs
with the calciﬁed cartilaginous interfacewas increased signiﬁcantly
compared to those without it, functionally validating its intended
effect. The hyaline quality of non-mineralized cartilage was
demonstrated by the accumulation of collagen type II and the lack
of mineral or collagen type I. Further study is required to determine
whether this osteochondral-like tissue formation will occur on
substrates other than hydroxyapatite-coated calcium poly-
phosphate substrate.
Thus far, approaches to induce selective mineralization of
BMSC-derived cartilage and create this interface include delivery of
bioactive signals either locally via microspheres23 or by using gra-
dients generated by a bioreactor24 to undifferentiated BMSCs
seeded in scaffolds. In another approach, BMSCs predifferentiated
to chondrocytes and osteoblasts are seeded into appropriatelocations within scaffolds25,26. For both strategies, use of exogenous
scaffolds is necessary, which has the potential to hinder host
integration and tissue regeneration27. Matching the rate of scaffold
degeneration to the rate of tissue accumulation remains a challenge
when employing scaffolds22,28. Synthetic materials also accumulate
wear over time, andmay provide a focal point for shear failure if not
replaced with new tissue. On the other hand, if the rate of scaffold
degradation exceeds the rate of cellular remodeling, the mechani-
cal integrity is compromised and the construct would fail under
load. A scaffold-free approach obviates this issue altogether; how-
ever, this necessitated an alternative strategy to specify the location
of the calciﬁed interface.
The development of our two-stage culture protocol was ﬁrst
enabled by the observation that BMSC-derived predifferentiated
chondrocytes formed mineralized cartilage at the tissue's superﬁ-
cial aspect with mineral-inducing stimulus. Given that T3 was
delivered to the tissue through culture media, and that the location
of calciﬁed cartilage did not changewith tissue thickness, this effect
was likely due to T3 diffusion into the tissue. As there was no
scaffold present, selective delivery of T3 to the interface was difﬁ-
cult to achieve with media alone. To circumvent this, we seeded a
small number of cells on the calcium polyphosphate in the pres-
ence of T3. This generated thin cartilaginous tissue, forcing
mineralization to take place juxtaposed to the porous calcium
polyphosphate substrate. This enabled the subsequent formation of
a continuous layer of non-mineralized cartilage formed by the same
cell type in the absence of T3. The presence of collagen types II, X
and proteoglycans in the calciﬁed interface, as well as the absence
of collagen type I, is an important ﬁnding in our study. Taken
together with the ﬁnding that T3-treated cells expressed hyper-
trophic chondrocyte makers, this demonstrates that the interface is
cartilaginous, not osseous, successfully recapitulating characteris-
tics of the native articular cartilage-subchondral bone interface.
Histology showed that the layer of non-mineralized cartilage
successfully fused to the underlying T3-treated tissue. Interestingly,
ﬁssures were observed if the intended interfacial tissue (i.e., the
ﬁrst layer) was not treated with T3, and the total thickness of
cartilage tissues on these constructs was increased, with an uneven
distribution of the extracellular matrix. There are two possible
explanations for these results. One is that the manner that the
interfacial layer grows may affect integration, as BMSC-derived
chondrocytes share many characteristics with proliferating carti-
lage29 that grows appositionally. In development, Indian hedgehog,
FGF and BMP signaling pathways regulate this appositional
growth30; however, in an in vitro system, absence of such complex
regulation may allow the interfacial layer to expand laterally. The
presence of tubing around the constructs prevented lateral
expansion by conﬁnement, which could have resulted in lateral
mechanical stress and caused the tissue to buckle and shear. This
W.D. Lee et al. / Osteoarthritis and Cartilage 23 (2015) 1307e13151314was not the case for T3-stimulated interfacial layer, whose behavior
may more resemble terminal hypertrophic chondrocytes, as evi-
denced by their mineralized matrix. Terminal hypertrophic chon-
drocytes do not proliferate and eventually undergo apoptosis upon
vascularization of matrix and bone formation31. Alternatively, the
T3 treatment may have affected tissue fusion. Pellets of human
MSCs undergoing chondrogenesis have been shown to accumulate
tenascin along the outer surface that prevented them from fusing
with one another32. The ﬁssure between the two layers of non-
mineralizing cartilage may stem from a similar boundary-setting
phenomenon, whether driven by tenascin accumulation or
otherwise.
Sheep gait studies estimate the maximum anterioposterior
shear stress in a stiﬂe joint to be about 500 kPa33,34, which is
equivalent to approximately 9 N of peak shear force in our study.
However, using our methodology the peak shear force of native
cartilage interface could not be measured, as it withstood the
maximum load (80 N) without shear failure. In healthy cartilage,
collagen ﬁbrils run orthogonally through the tidemark plane, which
would confer a high resistance against failure in our mode of study.
Although our multiphasic construct possesses inferior interfacial
shear strength compared to articular cartilage, it still represented a
four-fold improvement over the non-mineralized control, and
sheep gait studies suggest that this improvement is adequate for
preventing delamination.
Importantly, this protocol can be expanded to generate large,
anatomically shaped osteochondral-like constructs as re-
placements for damaged joint tissues. Protocols have been devel-
oped to generate ~108 BMSCswith chondrogenic potential in a good
manufacturing practices-complaint manner35,36, which can be used
to generate sufﬁciently large numbers of chondrocytes to cover a
large articular surface. We have previously shown that calcium
polyphosphate powders can be used in additive manufacturing
methods to generate substrates of required shape and size37. Cal-
cium polyphosphate formed in this way exhibited the same degree
of osseointegration after implantation as those produced conven-
tionally38. As such, preclinical studies are warranted to determine if
these osteochondral-like constructs with a mineralized cartilagi-
nous interface could repair joint defects in vivo.
Conclusion
Using BMSCs as a single cell source, an osteochondral-like
construct comprised of hyaline cartilage and porous bone substi-
tute was created with a ZCC interfacing them. The novel, two-step
cell culture strategy employed no exogenous scaffolds, just a sub-
strate on which to form tissue. The presence of calciﬁed cartilage
increased the shear load that the construct could withstand at the
interface. As no xenogeneic material was used at any point during
culture, this strategy can be directly translated into preclinical
studies to determine whether these constructs can repair joint
defects in vivo.
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